Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth.

George Whipple Laboratory for Cancer Research, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, New York 14642, USA.
Molecular Endocrinology (Impact Factor: 4.2). 03/2007; 21(2):343-58. DOI: 10.1210/me.2006-0104
Source: PubMed

ABSTRACT The androgen receptor (AR) requires coregulators for its optimal function. However, whether AR coregulators further need interacting protein(s) for their proper function remains unclear. Here we describe transgelin as the first ARA54-associated negative modulator for AR. Transgelin suppressed ARA54-enhanced AR function in ARA54-positive, but not in ARA54-negative, cells. Transgelin suppressed AR transactivation via interruption of ARA54 homodimerization and AR-ARA54 heterodimerization, resulting in the cytoplasmic retention of AR and ARA54. Stable transfection of transgelin in LNCaP cells suppressed AR-mediated cell growth and prostate-specific antigen expression, whereas this suppressive effect was abolished by the addition of ARA54-small interfering RNA. Results from tissue surveys showing decreased expression of transgelin in prostate cancer specimens further strengthened the suppressor role of transgelin. Our findings reveal the novel mechanisms of how transgelin functions as a suppressor to inhibit prostate cancer cell growth. They also demonstrate that AR coregulators, like ARA54, might have dual in vivo roles functioning as both a direct coactivator and as an indirect mediator in AR function. The finding that a protein can modulate AR function without direct interaction with AR might provide a new therapeutic approach, with fewer side effects, to battle prostate cancer by targeting AR indirectly.

Download full-text


Available from: Yu-Jia Chang, May 12, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metastatic dissemination of primary tumors is responsible for 90% of colorectal cancer (CRC) deaths. The presence of positive lymph nodes, which separates stage I/II from stage III CRC, is a particularly key factor in patient management. Here, we describe results of a quantitative proteomic survey to identify molecular correlates of node status. Laser capture microdissection and two-dimensional difference gel electrophoresis were used to establish expression profiles for 980 discrete protein features in 24 human CRC specimens. Protein abundances were determined with a median technical coefficient of variation of 10%, which provided an ability to detect small differences between cancer subtypes. Transgelin, a 23-kDa actin-binding protein, emerged as a top-ranked candidate biomarker of node status. The area under the receiver operating characteristic curve for transgelin in predicting node status was 0.868 (P = .002). Significantly increased frequency of moderate- and high-level transgelin expression in node-positive CRC was also seen using semiquantitative immunohistochemistry to analyze 94 independent CRC specimens on tissue microarrays (P = .036). Follow-up studies in CRC cell lines demonstrated roles for transgelin in promoting invasion, survival, and resistance to anoikis. Transgelin localizes to the nucleus of CRC cells, and its sequence and properties suggest that it may participate in regulation of the transcriptional program associated with the epithelial-to-mesenchymal transition.
    Neoplasia (New York, N.Y.) 10/2009; 11(9):864-73. DOI:10.1593/neo.09542 · 5.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The androgen depletion therapy (ADT) has become the major treatment for the cancer patients through the use of chemical castration and/or antiandrogens, yet the therapy eventually fails and cancers progress to more advanced stages. The mutation, amplification, overexpression of AR, and cross-talk between AR, AR co-regulators, and other growth factor pathways have provided potential explanations for the failure of androgen ablation therapies in some cases. However, whether the differential AR roles in different types of prostate cells could contribute to the failure of ADT remains unclear and will be the focus of this review. AR expresses in both stromal and epithelial compartments of prostate. It has been shown that there are three basic types of prostatic epithelial cells: (i) cytokeratin 8 (CK8)-positive, CK5-negative luminal cells, (ii) CK5/CK8-double positive intermediate cells, and (iii) CK8-negative, CK5-positive basal cells. In addition to prostatic stromal cells, AR expression could be detected in some basal cells, some intermediate cells, and all luminal cells in prostate. By Cre-LoxP strategy, the prostate epithelium-specific AR knockout (pes-ARKO) and inducible-cre ARKO mice were recently established and have allowed the field to address the differential and distinct AR roles in different types of prostatic cells. These ARKO mice were bred with TRAMP prostate cancer model, and results from these models suggest that (i) prostatic epithelial AR plays dual roles as a suppressor of basal cell proliferation and as a survival factor for luminal cells, and (ii) the stromal AR plays a proliferator role to support the epithelial cell survival and proliferation. Using microarray analysis of primary tumor cells isolated from the prostate tumors of pes-ARKO-TRAMP mice, it was found that a series of metastatic genes were altered and responsible for the higher invasiveness and metastatic rates. These recent ARKO animal studies not only advance our understanding of the differential roles of AR in different type of prostatic cells, but also closely reflect the pathological changes for the patients undergoing the ADT. Together, these findings provide new evidences to support the potential beneficial effects of intermittent ADT therapy, and they also urge the development of cell type and stage selective anti-AR therapies for the prostate cancer patients.
    12/2008: pages 73-89;
  • [Show abstract] [Hide abstract]
    ABSTRACT: To find a biomarker for gastric adenocarcinomas (GA). Ten protein expression profiles of GA and paired non-neoplastic mucosa tissues were analyzed by two-dimensional gel electrophoresis. Forty-two protein spots that were differentially expressed by twofold or greater between cancer and normal mucosa tissue were excised and identified by MALDI-TOF/TOF MS. One of the over-expressed proteins identified in GA was transgelin, which was chosen for further verification by immunohistochemistry and western blotting. Forty-two distinct proteins that were differentially expressed at least twofold between the tissues were identified. Expression of 29 of these proteins was decreased (ratio >or= 2, P < 0.01), including adenosine deaminase; and 13 proteins displayed over-expression in cancer tissue (ratio >or= 2, P < 0.01), including transgelin. The results of immunohistochemistry confirmed that transgelin was indeed over-expressed in 22 cases of GA (22/41, 53.66%), with strong cytoplasmic staining in cancer cells of positive samples, this was absent in most paired non-neoplastic mucosa cells or gastric ulcer tissues (n = 20). Transgelin was found over-expressed in 21 samples of cancer tissue (21/41, 51.22%) when detected by western blot. This work demonstrates that differentially expressed proteins can be identified by proteomics technology combined with immunohistochemistry and western blot analyses. We have identified one such protein, transgelin, as a novel biomarker for GA.
    Journal of Cancer Research and Clinical Oncology 05/2008; 134(11):1219-27. DOI:10.1007/s00432-008-0398-y · 3.01 Impact Factor